Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
Xconomy
APRIL 26, 2019
Biogen’s (NASDAQ: BIIB ) earnings call this week was the first since its Alzheimer’s drug aducanumab failed in a Phase 3 study and eviscerated the company’s shares. But it’s earnings season now, so some of them don’t have much choice. CEO Michel Vounatsos acknowledged the drug didn’t work.
Let's personalize your content